Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Tapentadol ER in Painful Diabetic Peripheral Neuropathy
NCT01063868Phase 3Terminated
- Sponsor
- Johnson & Johnson
- Start
- Jan 2010
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tapentadol in diabetic peripheral neuropathy (DPN), sponsored by Johnson & Johnson. Started Jan 2010; status: terminated.
02
Drugs
tapentadol
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT01063868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01063868.